Patents by Inventor Ranjit Bhardwaj

Ranjit Bhardwaj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8158767
    Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: April 17, 2012
    Assignee: TheraVision GmbH
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff
  • Publication number: 20110008341
    Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.
    Type: Application
    Filed: July 13, 2009
    Publication date: January 13, 2011
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff
  • Publication number: 20100098686
    Abstract: A compound comprising at least a structural entity which binds C-reactive protein (CRP) or parts of it or CRP in its monomeric, pentameric or multimeric form, preferably human CRP and which a.) blocks one or more CRP functions on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes CRP from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.
    Type: Application
    Filed: September 28, 2009
    Publication date: April 22, 2010
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff
  • Patent number: 7579437
    Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence (I) with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: August 25, 2009
    Assignee: TheraVision GmbH
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff
  • Publication number: 20070149450
    Abstract: A compound comprising at least a structural entity which binds C-reactive protein (CRP) or parts of it or CRP in its monomeric, pentameric or multimeric form, preferably human CRP and which a) blocks one or more CRP functions on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes CRP from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.
    Type: Application
    Filed: February 26, 2004
    Publication date: June 28, 2007
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff
  • Publication number: 20070148162
    Abstract: The present invention relates to the identification of molecules, which are specific to CD80 and CD86 antigens. Also preferably, such antibodies are capable of inhibiting the binding of CD28 and CTLA4 to those receptors. Those molecules are able to inhibit T cell mediated immune reactions.
    Type: Application
    Filed: February 26, 2004
    Publication date: June 28, 2007
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff
  • Publication number: 20060264613
    Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence (I) with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.
    Type: Application
    Filed: February 27, 2004
    Publication date: November 23, 2006
    Inventors: Ranjit Bhardwaj, Birgit Vogt, Ahmed Sheriff